Evidence mapPaperPMID 39747575Full record

ArticleScientific reports2025

Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension.

Justin H Berger, Yuji Shi, Timothy R Matsuura, Kirill Batmanov, Xian Chen, Kelly Tam, Mackenzie Marshall, Richard Kue, Jiten Patel, Renee Taing and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Justin H BergerCardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA, USA. j.berger@wustl.edu.
Yuji ShiInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Timothy R MatsuuraCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kirill BatmanovCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xian ChenDepartment of Pediatrics, Washington University School of Medicine, 660 S. Euclide, MSC 8116-0043-08, St. Louis, MO, 63110, USA.
Kelly TamInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Mackenzie MarshallInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Richard KueInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Jiten PatelCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Renee TaingCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Russell CallawayCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Joanna GriffinCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Attila KovacsDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Dinesh Hirenallur-ShanthappaInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Russell MillerInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Bei B ZhangInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Rachel J Roth FlachInternal Medicine Research Unit, Pfizer Worldwide Research, Development & Medical, Cambridge, USA.
Daniel P KellyCardiovascular Institute, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · 1985 to 2025
$79.7M
Univ of Pennsylvania Diabetes Endocrinology Res CTRP30DK019525 · UNIVERSITY OF PENNSYLVANIA · 1986 to 2025
$10.9M
PILOT--THE ROLE OF SRCASM IN EPITHELIAL DIFFERENTIATIONP30DK050306 · UNIVERSITY OF PENNSYLVANIA · 1997 to 2025
$7.2M
Washington University Nutrition Obesity Research CenterP30DK056341 · WASHINGTON UNIVERSITY · 1999 to 2025
$5.7M
Training Program in Cardiovascular Biology and MedicineT32HL007843 · NHLBI · UNIVERSITY OF PENNSYLVANIA · 1996 to 2025
$3.1M
Pediatric Scholars ProgramK12HD043245 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph W. St. Geme · 2003 to 2022
$2.1M
REGULATION OF FATTY ACID OXIDATION DURING CARDIAC GROWTHR01HL058493 · WASHINGTON UNIVERSITY · 1998 to 2005
$1.7M
American Heart Association 24CDA1269277NCI NIH HHS P30 CA016520NHLBI NIH HHS R01 HL058493NHLBI NIH HHS R01 HL128349NHLBI NIH HHS R01 HL151345NHLBI NIH HHS T32 HL007843NICHD NIH HHS K12 HD043245NIDDK NIH HHS P30 DK019525NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30 DK056341NIH HHS K12HD043245NIH HHS R01 HL128349NIH HHS S10 OD016393
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is increasingly common but its pathogenesis is poorly understood. The ability to assess genetic and pharmacologic interventions is hampered by the lack of robust preclinical mouse models of HFpEF. We developed a novel "two-hit" model, which combines obesity and insulin resistance with chronic pressure overload to recapitulate clinical features of HFpEF. C57Bl6/NJ mice fed a high-fat diet (HFD) for > 10 weeks were administered an AAV8-driven vector resulting in constitutive overexpression of mouse Renin1d. HFD-Renin (aka "HFpEF") mice demonstrated obesity and insulin resistance, moderate left ventricular hypertrophy, preserved systolic function, and diastolic dysfunction indicated by echocardiographic measurements; increased left atrial mass; elevated natriuretic peptides; and exercise intolerance. Transcriptomic and metabolomic profiling of HFD-Renin myocardium demonstrated upregulation of pro-fibrotic pathways and downregulation of metabolic pathways, in particular branched chain amino acid catabolism, similar to human HFpEF. Treatment with empagliflozin, an effective but incompletely understood HFpEF therapy, improved multiple endpoints. The HFD-Renin mouse model recapitulates key features of human HFpEF and will enable studies dissecting the contribution of individual pathogenic drivers to this complex syndrome. Additional preclinical HFpEF models allow for orthogonal studies to increase validity in assessment of interventions.

Indexed as

Diet, High-FatDisease Models, AnimalHeart FailureHypertensionMice, Inbred C57BLObesityReninStroke VolumeAnimalsInsulin ResistanceMaleMiceReninCardiovascular diseaseDiastolic dysfunctionHeart failure with preserved ejection fractionMouse models

Identifiers

PMID39747575
PMCPMC11696687

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.